Taverna Cecilia, Agaimy Abbas, Franchi Alessandro
Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy.
Institute of Pathology, Comprehensive Cancer Center (CCC) Erlangen-EMN, 91054 Erlangen, Germany.
Cancers (Basel). 2022 Mar 12;14(6):1463. doi: 10.3390/cancers14061463.
Sinonasal carcinomas are a heterogeneous group of rare tumors, often with high-grade and/or undifferentiated morphology and aggressive clinical course. In recent years, with increasing molecular testing, unique sinonasal tumor subsets have been identified based on specific genetic alterations, including protein expression, chromosomal translocations, specific gene mutations, or infection by oncogenic viruses. These include, among others, the identification of a subset of sinonasal carcinomas associated with HPV infection, the identification of a subset of squamous cell carcinomas with alterations, and of rare variants with chromosomal translocations ( and others). The group of sinonasal adenocarcinomas remains very heterogeneous at the molecular level, but some recurrent and potentially targetable genetic alterations have been identified. Finally, poorly differentiated and undifferentiated sinonasal carcinomas have undergone a significant refinement of their subtyping, with the identification of several new novel molecular subgroups, such as NUT carcinoma, mutated sinonasal undifferentiated carcinoma and SWI/SNF deficient sinonasal malignancies. Thus, molecular profiling is progressively integrated in the histopathologic classification of sinonasal carcinomas, and it is likely to influence the management of these tumors in the near future. In this review, we summarize the recent developments in the molecular characterization of sinonasal carcinomas and we discuss how these findings are likely to contribute to the classification of this group of rare tumors, with a focus on the potential new opportunities for treatment.
鼻窦癌是一组异质性罕见肿瘤,通常具有高级别和/或未分化形态以及侵袭性临床病程。近年来,随着分子检测的增加,基于特定基因改变已鉴定出独特的鼻窦肿瘤亚群,包括蛋白质表达、染色体易位、特定基因突变或致癌病毒感染。其中包括鉴定出与HPV感染相关的鼻窦癌亚群、具有特定改变的鳞状细胞癌亚群以及具有染色体易位的罕见变体(等等)。鼻窦腺癌组在分子水平上仍然非常异质性,但已鉴定出一些复发性且可能可靶向的基因改变。最后,低分化和未分化鼻窦癌在亚型分类方面有了重大改进,鉴定出了几个新的分子亚群,如NUT癌、BRAF突变的鼻窦未分化癌和SWI/SNF缺陷型鼻窦恶性肿瘤。因此,分子谱分析正逐渐融入鼻窦癌的组织病理学分类中,并且很可能在不久的将来影响这些肿瘤的管理。在本综述中,我们总结了鼻窦癌分子特征的最新进展,并讨论了这些发现如何可能有助于对这组罕见肿瘤进行分类,重点关注潜在的新治疗机会。